ATE474604T1 - Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen - Google Patents

Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen

Info

Publication number
ATE474604T1
ATE474604T1 AT03812366T AT03812366T ATE474604T1 AT E474604 T1 ATE474604 T1 AT E474604T1 AT 03812366 T AT03812366 T AT 03812366T AT 03812366 T AT03812366 T AT 03812366T AT E474604 T1 ATE474604 T1 AT E474604T1
Authority
AT
Austria
Prior art keywords
angiogenesis
dependent symptoms
prevention
compositions
treatment
Prior art date
Application number
AT03812366T
Other languages
English (en)
Inventor
Kazuya Hiraoka
Seiji Yamamoto
Yasufumi Kaneda
Toshio Ogihara
Ryuichi Morishita
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of ATE474604T1 publication Critical patent/ATE474604T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
AT03812366T 2002-12-02 2003-12-02 Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen ATE474604T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43047802P 2002-12-02 2002-12-02
PCT/JP2003/015400 WO2004050126A2 (en) 2002-12-02 2003-12-02 Compositions for treating or preventing angiogenesis-dependent symptoms

Publications (1)

Publication Number Publication Date
ATE474604T1 true ATE474604T1 (de) 2010-08-15

Family

ID=32469479

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03812366T ATE474604T1 (de) 2002-12-02 2003-12-02 Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen

Country Status (9)

Country Link
US (1) US7259149B2 (de)
EP (1) EP1567197B1 (de)
JP (1) JP4623719B2 (de)
CN (1) CN1717254A (de)
AT (1) ATE474604T1 (de)
AU (1) AU2003302590B2 (de)
CA (1) CA2507534A1 (de)
DE (1) DE60333476D1 (de)
WO (1) WO2004050126A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1182874C (zh) * 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
US20090012498A1 (en) * 2004-10-29 2009-01-08 Yoshiki Sawa Gene therapy for treatment of heart failure
WO2007089780A2 (en) * 2006-01-30 2007-08-09 Licentia, Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
RU2542385C2 (ru) 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5941431U (ja) * 1982-09-07 1984-03-16 斎藤　春雄 治療用高圧タンクにおける緊急脱出扉装置
JPS6183121A (ja) * 1984-10-01 1986-04-26 Green Cross Corp:The 虚血性潰瘍治療剤
US20020137707A1 (en) * 1997-12-30 2002-09-26 Monahan Sean D. Intravascular delivery of non-viral nucleic acid
WO1997040679A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6312663B1 (en) * 1999-03-19 2001-11-06 Joseph V. Boykin, Jr. Prediction of diabetes impaired wound healing by urinary nitrate assay
MXPA01010459A (es) * 1999-04-16 2003-08-20 Univ Yale Mutaciones de sintasa de oxido nitrico endotelial, utiles para terapia con genes y su depuracion terapeutica.
JP2001017188A (ja) * 1999-04-22 2001-01-23 Kyowa Hakko Kogyo Co Ltd 新規なｖｅｇｆ／ｐｄｇｆ様因子
WO2002000258A1 (en) * 2000-06-27 2002-01-03 Anges Mg, Inc. Medicinal compositions for angiogenic therapy
EP2578388A3 (de) * 2002-07-18 2013-08-14 Mitsubishi Rayon Co., Ltd. Verfahren zur Herstellung von Prepreg
JP4420633B2 (ja) 2002-08-08 2010-02-24 アンジェスＭｇ株式会社 血管新生治療剤
JP4603978B2 (ja) * 2002-11-28 2010-12-22 三菱レイヨン株式会社 繊維強化複合材料成形品の製造方法

Also Published As

Publication number Publication date
WO2004050126A2 (en) 2004-06-17
DE60333476D1 (de) 2010-09-02
AU2003302590A1 (en) 2004-06-23
EP1567197B1 (de) 2010-07-21
CN1717254A (zh) 2006-01-04
CA2507534A1 (en) 2004-06-17
US20060135452A1 (en) 2006-06-22
JP4623719B2 (ja) 2011-02-02
EP1567197A2 (de) 2005-08-31
AU2003302590B2 (en) 2008-11-06
US7259149B2 (en) 2007-08-21
JP2006511515A (ja) 2006-04-06
WO2004050126A3 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
MX2010004074A (es) Combinacion 059.
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE533484T1 (de) Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes
EP1545587A4 (de) Lactoferrin-zusammensetzungen und wundbehandlungsverfahren
BRPI0407694A (pt) métodos de usar células derivadas do tecido adiposo no tratamento de condições cardiovasculares
MX340515B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
ATE253932T1 (de) Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien
PL1692516T3 (pl) Sposób terapii
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
DE60203847D1 (de) Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE474604T1 (de) Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen
DE602005008013D1 (de) Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
IL164314A (en) Method to inhibit cell growth using oligonucleotides
MX2022009712A (es) Tratamiento de infeccion por coronavirus con interferon lambda.
ATE458495T1 (de) Therapeutische zubereitung für autoimmune erkrankungen
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
ATE367823T1 (de) E-selectin zur behandlung oder vorbeugung von schlaganfall
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
PL1599211T3 (pl) Zastosowanie izorhamnetyny do leczenia nastrojów i chorób depresyjnych
ATE466587T1 (de) Valeriana officinalis extrakt zur behandlung von schlafapnoe oder hypopnoe
DE602005016198D1 (de) Verwendung von Hülsenfrüchten zur Herstellung von Produkten zum Schutz oder Behandlung von radiotherapie-bedingten Hautschäden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties